cedars-sinai medical center, lung cancer, medicine, national institutes of health

Some lung cancer patients’ lifetimes were extended by a new medication combination.

When compared to standard treatment, the combination of ramucirumab and pembrolizumab decreased the risk of mortality by 31% in patients with advanced non-small cell lung cancer that had progressed on previous immunotherapy.

According to a study done under the Lung Cancer Master Protocol (Lung-MAP), patients with advanced non-small cell lung cancer whose cancer had advanced on prior immunotherapy lived noticeably longer when treated with ramucirumab (Cyramza) and pembrolizumab (Keytruda) combined than when treated with one of the current standard therapies for this type of cancer.

cedars-sinai medical center, lung cancer, medicine, national institutes of health

Karen Reckamp, MD, MS, a SWOG investigator who is director of the Division of Medical Oncology and associate director of clinical research at Cedars-Sinai Medical Center, Los Angeles. Credit: Cedars-Sinai Medical Center

The hazard ratio (with an 80 percent confidence interval) for overall survival (OS) time for patients on the investigational arm versus the standard of care arm was 0.69 (0.51-0.92). The two arms’ respective median OS times were 14.5 and 11.6 months.

The findings were published in the Journal of Clinical Oncology and were also presented at the American Society of Clinical Oncology (ASCO) 2022 annual conference in Chicago (abstract 9004).

The Lung-MAP trial, the first lung cancer precision medicine trial funded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), was conducted as part of the S1800A study, which was carried out within the NCI’s National Clinical Trials Network (NCTN) and the NCI Community Oncology Research Program (NCORP).

Karen Reckamp, MD, MS, assistant director of clinical research and head of the Division of Medical Oncology at Cedars-Sinai Medical Center in Los Angeles, is the lead investigator for the S1800A study. The trial’s findings were presented by her at the ASCO conference.

“This is the first trial to show a survival benefit with ICI and VEGFR inhibition for patients with advanced lung cancer who have experienced tumor progression on prior ICI,” Reckamp said.

Pembrolizumab is one of a class of immunotherapy drugs known as immune checkpoint inhibitors (ICIs), and ramucirumab is a vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor, a class of drugs that block an enzyme needed to form blood vessels.

The randomized phase 2 S1800A study enrolled 136 eligible patients with stage IV or recurrent non-small cell lung cancer. These patients had been previously treated with ICIs. In all cases, patients’ tumors eventually became resistant to these drugs and grew or spread before the patient enrolled in the S1800A trial.

The trial accrued rapidly and with a diverse population, in large part because of the robust outreach of the Lung-MAP master screening protocol. Roy S. Herbst, MD, Ph.D., deputy director of Yale Cancer Center, Lung-MAP founding and principal investigator, and senior author of the paper commented, “The unique nature of the public-private partnership of Lung-MAP, supported by the expansive and diverse nature of the NCI’s NCTN and NCORP, allowed us to bring these new therapies to patients with advanced lung cancer nationwide at no cost to patients – an important improvement in patient access.”

Overall survival was the trial’s primary endpoint. Secondary endpoints included progression-free survival time (PFS) and objective response rate (ORR). The researchers found no significant difference between the arms in PFS (hazard ratio [80 percent confidence interval]: 0.86 [0.66-1.14]; medians: 4.5 months on the ramucirumab plus pembrolizumab arm vs. 5.2 months on the standard of care arm) or in ORR (22 percent vs. 28 percent).

Grade 3 or higher adverse events (side effects) related to the treatment were recorded in 42 percent of the patients on the ramucirumab plus pembrolizumab arm and in 60 percent of patients on the standard of care arm.

Treatment on the trial’s control arm was chosen by the physician and patient from among a set of four standard chemotherapy options: docetaxel plus ramucirumab, docetaxel alone, gemcitabine, or pemetrexed. Approximately two-thirds of patients on standard therapy received docetaxel and ramucirumab as the most active therapy approved in this setting.

The researchers note that S1800A’s relatively small sample size means the trial’s results cannot be seen as definitive, and the combination should be studied in a larger trial.

“These results represent a potential paradigm-changing regimen in a setting where limited options exist,” Reckamp said. “A phase 3 trial of the combination is warranted to better evaluate the impact.”

Reference: “Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A” by Karen L. Reckamp, MD, Mary W. Redman, Ph.D., Konstantin H. Dragnev, MD, Katherine Minichiello, MS, Liza C. Villaruz, MD, Bryan Faller, MD, Tareq Al Baghdadi, MD, Susan Hines, MD, Leah Everhart, BS, Louise Highleyman, BA, Vassiliki Papadimitrakopoulou, MD, David R. Gandara, MD, Karen Kelly, MD and Roy S. Herbst, MD, Ph.D., 20 July 2022, Journal of Clinical Oncology.
DOI: 10.1200/JCO.22.00912

The study was funded by the NIH/National Cancer Institute, the Foundation for the National Institutes of Health, Eli Lilly and Company, and Merck Sharp and Dohme.

TECH NEWS RELATED

Alain Aspect, Nobel-winning father of quantum entanglement

Alain Aspect, one of three physics Nobel winners, helped pave the way for what he calls the ‘second quantum revolution’ Alain Aspect, who won a long-expected Nobel Physics Prize on Tuesday, not only helped prove the strange theory of quantum entanglement but also inspired a generation of physicists in ...

View more: Alain Aspect, Nobel-winning father of quantum entanglement

Reports say the CIA is trying to resurrect woolly mammoths

There is a lot of skepticism around the prospect of reviving extinct animals like the woolly mammoth. Despite the skepticism, though, it appears the CIA is going all in on investing in mammoth resurrection tech. With the ongoing changes happening around the globe due to climate change, bringing extinct ...

View more: Reports say the CIA is trying to resurrect woolly mammoths

The Mediterranean Sea Rising Temperatures Trigger the Formation of CO2-emitting Crystals

According to the United Nations Climate Action, as the ocean warms from the excess heat and energy, there are unmatched cascading effects, resulting in ice melting, sea level rise, marine heat waves, and ocean acidification. More concerning climate change indicators include the oceans’ inability to absorb heat generated by rising greenhouse ...

View more: The Mediterranean Sea Rising Temperatures Trigger the Formation of CO2-emitting Crystals

Ancient chemistry may explain why living things use ATP as the universal energy currency

Molecular dynamic simulation of ADP and acetyl phosphate. Credit: Aaron Halpern, UCL (CC-BY 4.0, creativecommons.org/licenses/by/4.0/) A simple two-carbon compound may have been a crucial player in the evolution of metabolism before the advent of cells, according to a new study published October 4 in the open access journal PLOS ...

View more: Ancient chemistry may explain why living things use ATP as the universal energy currency

New book examines gender on legal response to domestic violence

Credit: Pixabay/CC0 Public Domain Over the past 40 years, considerable progress has been made in lowering rates of domestic violence (DV) in our communities. However, this progress has been uneven due to continuing misconceptions about the causes and dynamics of domestic violence. “Gender and Domestic Violence: Contemporary Legal Practice ...

View more: New book examines gender on legal response to domestic violence

Study: Black prosecutors are more punitive toward Black and Latinx defendants

Credit: CC0 Public Domain Prosecutors exert considerable power in the criminal justice system, and while defendants are predominantly Black and Latinx, prosecutors are overwhelmingly White. Despite calls for addressing racial disparities in this field, we know little about whether recruiting minority prosecutors would yield more equitable outcomes for defendants. ...

View more: Study: Black prosecutors are more punitive toward Black and Latinx defendants

Online fandom communities can facilitate state censorship, according to new research

Analytical procedure. Credit: New Media & Society (2022). DOI: 10.1177/14614448221113923 Authoritarian regimes worldwide have embraced the digital age. And they have been generally effective at limiting the online presence of perceived adversaries within their borders—from intellectual dissidents to transnational activists. However, as a new study published in the journal ...

View more: Online fandom communities can facilitate state censorship, according to new research

Nirit Weiss-Blatt

Dr. Nirit Weiss-Blatt is the author of The TECHLASH and Tech Crisis Communication. She is a former Research Fellow at the University of Southern California’s Annenberg School for Communication and Journalism. Her expertise is in tech journalism. She is a contributor to Techdirt, and also has published in Newsweek ...

View more: Nirit Weiss-Blatt

How many innocent people is the plea bargain sending to prison?

Spectacular Planetary-Scale “Heat Wave” Discovered in Jupiter’s Atmosphere

Plastic gobbling enzymes in worm spit may help ease pollution

Holmes gets new hearing after disheveled gov’t witness shows up at her house

Both sides dig in as EPA's final decision on Pebble Mine nears

Quantum entanglement: the 'spooky' science behind physics Nobel

The Nobel winners who helped prove quantum 'spooky action'

Making tumor diagnosis kinder to kidneys

A quick look at the 2022 Nobel Prizes

Four from MIT receive NIH New Innovator Awards for 2022

Harpoon heads, sweeping tails: How predatory mosquito larvae capture prey

UK Scientists Discover Ultrarare Blood Group System

OTHER TECH NEWS

Top Car News Car News